CU20110228A7 - Compuestos útiles para tratar envejecimiento prematuro y en particular progeria - Google Patents
Compuestos útiles para tratar envejecimiento prematuro y en particular progeriaInfo
- Publication number
- CU20110228A7 CU20110228A7 CU20110228A CU20110228A CU20110228A7 CU 20110228 A7 CU20110228 A7 CU 20110228A7 CU 20110228 A CU20110228 A CU 20110228A CU 20110228 A CU20110228 A CU 20110228A CU 20110228 A7 CU20110228 A7 CU 20110228A7
- Authority
- CU
- Cuba
- Prior art keywords
- group
- premature aging
- hydroxyl
- alkyl
- useful compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010063493 Premature ageing Diseases 0.000 title abstract 2
- 208000032038 Premature aging Diseases 0.000 title abstract 2
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 title 1
- 208000007932 Progeria Diseases 0.000 title 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- -1 N-methylpiperazinyl group Chemical group 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a un compuesto (I) en donde: significa un grupo piridazina, pirimidina o pirazina, R independientemente representa un átomo de hidrógeno, átomo de halógeno o un grupo seleccionado de entre un grupo -CN, un grupo hidroxilo, un grupo -COOR1, un grupo fluoroalquilo de C1-C3, un grupo fluoroalcoxi de C1-C3, un grupo -NO2, un grupo -NriR2, un grupo alcoxi de C1-C4, un grupo fenoxi, y un grupo alquilo de C1-C3, el alquilo opcionalmente monosustituido por un grupo hidroxilo, n es 1, 2 o 3, n' es 1 o 2, R' es un átomo de hidrógeno, un átomo de halógeno o un grupo seleccionado entre un grupo alquilo de C1-C3, un grupo hidroxilo, un grupo -COOR1, un grupo -NO2, un grupo -NR1R2, un grupo morfolinilo o morfolino, un grupo N-metilpiperazinilo, un grupo fluoroalquilo de C1-C3, un grupo alcoxi de C1-C4, y un grupo -CN, Z es N o C, Y es N o C, Z es N o C, W es N o C, T es N o C, U es N o C, para utilizarse como un agente para la prevención, inhibición o tratamiento de afecciones patológicas o no patológicas involucradas con envejecimiento prematuro. Algunos de los compuestos son nuevos y también forman parte de la invención.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18654409P | 2009-06-12 | 2009-06-12 | |
| US18655209P | 2009-06-12 | 2009-06-12 | |
| EP20090305540 EP2266972A1 (en) | 2009-06-12 | 2009-06-12 | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
| EP09162630A EP2261214A1 (en) | 2009-06-12 | 2009-06-12 | Compounds useful to treat premature aging and in particular progeria |
| PCT/IB2010/052652 WO2010143170A2 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating premature aging and in particular progeria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20110228A7 true CU20110228A7 (es) | 2012-04-15 |
| CU24461B1 CU24461B1 (es) | 2020-01-03 |
Family
ID=43309298
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2011000228A CU24461B1 (es) | 2009-06-12 | 2010-06-14 | Compuestos útiles para tratar envejecimiento prematuro y en particular progeria |
| CUP2011000229A CU24124B1 (es) | 2009-06-12 | 2010-06-14 | N-fenil-naftalen-2-aminas sustituidas para el tratamiento del cáncer. |
| CUP2015000024A CU24245B1 (es) | 2009-06-12 | 2010-06-14 | QUINOLIN-6 AMINA Y QUINOLINA-7-AMINA DERIVADOS DE LA FÓRMULA (Id) y (Ir), Y SALES DERIVADAS |
| CU2011000230A CU24093B1 (es) | 2009-06-12 | 2010-06-14 | Derivados de isoquinolina vinculados al proceso de empalme celular |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2011000229A CU24124B1 (es) | 2009-06-12 | 2010-06-14 | N-fenil-naftalen-2-aminas sustituidas para el tratamiento del cáncer. |
| CUP2015000024A CU24245B1 (es) | 2009-06-12 | 2010-06-14 | QUINOLIN-6 AMINA Y QUINOLINA-7-AMINA DERIVADOS DE LA FÓRMULA (Id) y (Ir), Y SALES DERIVADAS |
| CU2011000230A CU24093B1 (es) | 2009-06-12 | 2010-06-14 | Derivados de isoquinolina vinculados al proceso de empalme celular |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US20120277230A1 (es) |
| EP (6) | EP2440547B1 (es) |
| JP (8) | JP6041671B2 (es) |
| KR (14) | KR102016892B1 (es) |
| CN (13) | CN103948594B (es) |
| AU (3) | AU2010258214B2 (es) |
| BR (5) | BRPI1012892B8 (es) |
| CA (5) | CA2965791C (es) |
| CU (4) | CU24461B1 (es) |
| DK (4) | DK2440547T3 (es) |
| ES (4) | ES2736198T3 (es) |
| FI (3) | FI3517534T3 (es) |
| HR (3) | HRP20230143T1 (es) |
| HU (2) | HUE045548T2 (es) |
| LT (1) | LT2440547T (es) |
| MX (10) | MX364989B (es) |
| PL (4) | PL2440547T3 (es) |
| PT (4) | PT2440547T (es) |
| RU (1) | RU2567752C2 (es) |
| SI (1) | SI2440547T1 (es) |
| TR (1) | TR201910781T4 (es) |
| WO (3) | WO2010143169A2 (es) |
| ZA (2) | ZA201109031B (es) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| HRP20191460T1 (hr) * | 2009-06-12 | 2019-11-15 | Abivax | Spojevi korisni za liječenje raka |
| MX364989B (es) | 2009-06-12 | 2019-05-17 | Abivax | Compuestos utiles para tratar envejecimiento prematuro y en particular progeria. |
| WO2011028947A2 (en) | 2009-09-03 | 2011-03-10 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| EP2661431B1 (en) | 2011-01-05 | 2018-07-11 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| US8916561B2 (en) | 2011-03-02 | 2014-12-23 | Bioenergenix, Llc | Substituted quinoxaline compounds for the inhibition of PASK |
| BR112013022147A2 (pt) | 2011-03-02 | 2017-04-25 | Bioenergenix | composto, composição farmacêutica, método de inibição da pask, método de tratamento de uma doença, método para alcançar um efeito em um paciente e método de tratamento de uma doença mediada pela pask |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| FR2987627B1 (fr) * | 2012-03-05 | 2016-03-18 | Splicos | Utilisation de rbm39 comme biomarqueur |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| EP2863920B1 (en) * | 2012-06-20 | 2023-03-22 | Eutropics Pharmaceuticals, Inc. | Quinoline derivatives for use in the tratment of breast cancer |
| TW201410657A (zh) | 2012-08-02 | 2014-03-16 | Endo Pharmaceuticals Inc | 經取代胺基－嘧啶衍生物 |
| US9487526B2 (en) | 2012-08-13 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Quinoxaline derivatives as GPR6 modulators |
| JP2014237624A (ja) * | 2012-10-23 | 2014-12-18 | 日本曹達株式会社 | ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤 |
| US20160038503A1 (en) | 2012-11-21 | 2016-02-11 | David Richard | Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives |
| GB201301571D0 (en) * | 2012-11-27 | 2013-03-13 | Fundanci N Pedro Barri De La Maza | Product and use |
| US20140194465A1 (en) * | 2013-01-04 | 2014-07-10 | Novarx Corporation | Compositions for treatment of cancer |
| EP2757161A1 (en) * | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| KR102326068B1 (ko) | 2013-07-05 | 2021-11-11 | 아비박스 | 레트로바이러스에 의해 야기되는 질병 치료에 유용한 이고리 화합물 |
| WO2015005491A1 (ja) | 2013-07-12 | 2015-01-15 | 国立大学法人京都大学 | 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法 |
| WO2015017788A1 (en) | 2013-08-01 | 2015-02-05 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
| JP6538044B2 (ja) | 2013-10-30 | 2019-07-03 | ユートロピクス ファーマシューティカルズ， インコーポレイテッド | 化学療法感受性および化学毒性を判定する方法 |
| JO3466B1 (ar) | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
| JP6526034B2 (ja) | 2014-02-14 | 2019-06-05 | 武田薬品工業株式会社 | Ｇｐｒ６のピリドピラジンモジュレーター |
| US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| WO2015144804A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
| JP6990586B2 (ja) | 2015-01-30 | 2022-01-12 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック | デルタ１３３ｐ５３ベータおよびデルタ１３３ｐ５３ガンマアイソフォームはがん幹細胞のバイオマーカーである |
| TWI834020B (zh) | 2015-02-10 | 2024-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| EP3059591A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| WO2017050865A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| WO2017050864A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | New compounds |
| DK3390364T3 (da) | 2015-12-17 | 2020-10-12 | Biokine Therapeutics Ltd | Små molekyler til hæmning af kemokinaktivitet og/eller cancercellevækst |
| EP3390378B1 (en) | 2015-12-17 | 2022-03-30 | AlonBio Ltd. | Small molecules against cancer |
| MA43954A (fr) * | 2016-02-03 | 2018-12-12 | Janssen Pharmaceutica Nv | Ligands d'imagerie tau-pet |
| WO2017158201A1 (en) | 2016-03-18 | 2017-09-21 | Ratiopharm Gmbh | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
| US11168068B2 (en) | 2016-07-18 | 2021-11-09 | Janssen Pharmaceutica Nv | Tau PET imaging ligands |
| AR112027A1 (es) | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| US10323289B2 (en) * | 2017-06-26 | 2019-06-18 | Institut Pasteur | Treatments to eliminate HIV reservoirs and reduce viral load |
| CH715452B1 (de) | 2017-08-29 | 2021-05-14 | Chulabhorn Found | Derivate und Zusammensetzung von Chinolin und Naphthyridin. |
| US12528810B2 (en) * | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| WO2019186277A1 (en) | 2018-03-28 | 2019-10-03 | Institut Pasteur | Ultrasensitive hiv-1 p24 detection assay |
| EP3594205A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| EP3594206A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
| EP3669874A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| AU2020276793A1 (en) | 2019-05-15 | 2022-01-20 | Alonbio Ltd. | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death |
| EP3858815A1 (en) | 2020-01-31 | 2021-08-04 | Abivax | Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| BR112022014772A2 (pt) * | 2020-01-31 | 2022-09-20 | Abivax | Dispersão sólida amorfa, composição farmacêutica e processos para a preparação destas |
| EP3858336A1 (en) | 2020-01-31 | 2021-08-04 | Abivax | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| JP2023521564A (ja) | 2020-03-20 | 2023-05-25 | アビバックス | コロナウイルス科ウイルス感染症を処置又は予防する為の化合物及びコロナウイルス科ウイルス感染症の発生を評価する方法及び使用方法 |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11780840B2 (en) | 2020-07-02 | 2023-10-10 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
| EP4063351A1 (en) | 2021-03-26 | 2022-09-28 | Abivax | Preparation method of quinoline derivative compounds |
| MX2023013972A (es) | 2021-05-27 | 2023-12-11 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto de quinolinamina, metodo de preparacion y aplicacion del mismo en productos farmaceuticos. |
| KR20230072900A (ko) | 2021-11-18 | 2023-05-25 | 동우 화인켐 주식회사 | 마이크로 led 구조체 및 이의 제조방법 |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
| WO2023138657A1 (zh) * | 2022-01-24 | 2023-07-27 | 江苏恒瑞医药股份有限公司 | 喹啉胺类化合物、其制备方法及其在医药上的应用 |
| TW202337453A (zh) | 2022-03-17 | 2023-10-01 | 美商英塞特公司 | 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物 |
| EP4624469A1 (en) | 2022-11-25 | 2025-10-01 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Quinoline amine compound crystal form and preparation method therefor |
| WO2025027388A1 (en) | 2023-08-01 | 2025-02-06 | Abivax | Obefazimod for treatment of ulcerative colitis |
| CN121532389A (zh) * | 2023-08-30 | 2026-02-13 | 江苏正大丰海制药有限公司 | 用于调节微小rna-124活性的化合物 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR400973A (fr) | 1909-03-19 | 1909-08-13 | Jean Victor Massillon | Nouveau sertisseur à main pour la fabrication des cartouches |
| GB585362A (en) | 1944-08-31 | 1947-02-05 | Francis Henry Swinden Curd | New heterocyclic compounds |
| BE486034A (es) | 1947-11-28 | |||
| DE958647C (de) | 1952-12-28 | 1957-02-21 | Hoechst Ag | Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen |
| FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
| FR2627493B1 (fr) * | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
| FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| DE60008509T2 (de) | 1999-04-05 | 2004-12-16 | City Of Hope, Duarte | Neue Hemmer von fortgeschrittenen Glykosilierungsendprodukten (AGEs) |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| DE10013318A1 (de) * | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| CZ20031986A3 (cs) | 2001-01-22 | 2003-12-17 | Memory Pharmaceuticals Corporation | N-substituované aniliny a difenylaminy inhibující PDE4 a farmaceutický prostředek, který je obsahuje |
| PL375552A1 (en) | 2002-05-22 | 2005-11-28 | Amgen Inc. | Vanilloid receptor ligands and their medical applications |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| AU2003256616B2 (en) * | 2002-07-19 | 2009-08-27 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs |
| FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
| WO2004078731A1 (en) | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Quinoline-carboxylic acids and the derivatives thereof, a focused library |
| CA2518398A1 (en) * | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
| FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| EP1680122A1 (en) * | 2003-10-16 | 2006-07-19 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for the treatment of cancer |
| JP4768628B2 (ja) * | 2003-11-19 | 2011-09-07 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋの二環系阻害剤及びその使用方法 |
| EP1814856A1 (en) * | 2004-11-12 | 2007-08-08 | Galapagos N.V. | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
| EP1853265B1 (en) | 2005-01-28 | 2016-01-27 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis |
| CN101213260A (zh) * | 2005-06-29 | 2008-07-02 | 株式会社Adeka | 树脂添加剂组合物和其树脂组合物 |
| FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
| WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| CN101663279A (zh) * | 2007-01-19 | 2010-03-03 | 阿迪生物科学公司 | Mek抑制剂 |
| FR2912745A1 (fr) | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
| US20100249184A1 (en) * | 2007-03-16 | 2010-09-30 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
| TWI371445B (en) * | 2007-05-17 | 2012-09-01 | Lg Chemical Ltd | New anthracene derivatives and organic electronic device using the same |
| UY31272A1 (es) * | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| CA2695456A1 (en) | 2007-08-15 | 2009-02-19 | Robert Dunn | 3' substituted compounds having 5-ht6 receptor affinity |
| WO2009029617A1 (en) * | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
| KR100974562B1 (ko) * | 2007-12-31 | 2010-08-06 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자 |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| CA2747790A1 (en) * | 2009-01-05 | 2010-07-08 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants |
| WO2010079123A2 (en) * | 2009-01-06 | 2010-07-15 | Dsm Ip Assets B.V. | Process for resveratrol intermediate |
| KR20110117652A (ko) * | 2009-01-06 | 2011-10-27 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 동맥경화증의 치료를 위한 ｂ세포 감소 제제 |
| MX364989B (es) | 2009-06-12 | 2019-05-17 | Abivax | Compuestos utiles para tratar envejecimiento prematuro y en particular progeria. |
| HRP20191460T1 (hr) * | 2009-06-12 | 2019-11-15 | Abivax | Spojevi korisni za liječenje raka |
| EP2266972A1 (en) | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
| US8962583B2 (en) | 2009-06-25 | 2015-02-24 | The Brigham And Women's Hospital, Inc. | Treatment of inflammatory diseases using miR-124 |
| EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| US20150272959A1 (en) | 2012-10-04 | 2015-10-01 | Oyagen, Inc. | Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| JP2015120566A (ja) * | 2013-12-20 | 2015-07-02 | ニチユ三菱フォークリフト株式会社 | 荷役車両 |
-
2010
- 2010-06-14 MX MX2015016293A patent/MX364989B/es unknown
- 2010-06-14 BR BRPI1012892A patent/BRPI1012892B8/pt active IP Right Grant
- 2010-06-14 WO PCT/IB2010/052651 patent/WO2010143169A2/en not_active Ceased
- 2010-06-14 KR KR1020197004607A patent/KR102016892B1/ko active Active
- 2010-06-14 KR KR1020187025626A patent/KR101982463B1/ko not_active Expired - Fee Related
- 2010-06-14 PL PL10757474.1T patent/PL2440547T3/pl unknown
- 2010-06-14 CU CU2011000228A patent/CU24461B1/es unknown
- 2010-06-14 PL PL19157827.7T patent/PL3517534T3/pl unknown
- 2010-06-14 KR KR1020197004606A patent/KR102016891B1/ko active Active
- 2010-06-14 HR HRP20230143TT patent/HRP20230143T1/hr unknown
- 2010-06-14 EP EP10757474.1A patent/EP2440547B1/en active Active
- 2010-06-14 FI FIEP19157827.7T patent/FI3517534T3/fi active
- 2010-06-14 CA CA2965791A patent/CA2965791C/en active Active
- 2010-06-14 MX MX2016007353A patent/MX367601B/es unknown
- 2010-06-14 AU AU2010258214A patent/AU2010258214B2/en active Active
- 2010-06-14 EP EP10728369.9A patent/EP2440546B1/en active Active
- 2010-06-14 ES ES10728368T patent/ES2736198T3/es active Active
- 2010-06-14 KR KR1020197004608A patent/KR102016893B1/ko active Active
- 2010-06-14 CU CUP2011000229A patent/CU24124B1/es active IP Right Grant
- 2010-06-14 CN CN201410106644.9A patent/CN103948594B/zh active Active
- 2010-06-14 PL PL10728368T patent/PL2440545T3/pl unknown
- 2010-06-14 MX MX2018009425A patent/MX373120B/es unknown
- 2010-06-14 HR HRP20230248TT patent/HRP20230248T1/hr unknown
- 2010-06-14 KR KR1020127000914A patent/KR20120051643A/ko not_active Ceased
- 2010-06-14 KR KR1020127000916A patent/KR101769616B1/ko active Active
- 2010-06-14 CN CN201710158473.8A patent/CN106928205B/zh active Active
- 2010-06-14 KR KR1020187025623A patent/KR101982461B1/ko not_active Expired - Fee Related
- 2010-06-14 US US13/377,745 patent/US20120277230A1/en not_active Abandoned
- 2010-06-14 MX MX2011013119A patent/MX353776B/es active IP Right Grant
- 2010-06-14 AU AU2010258295A patent/AU2010258295B2/en active Active
- 2010-06-14 PT PT107574741T patent/PT2440547T/pt unknown
- 2010-06-14 US US13/377,753 patent/US20120329796A1/en not_active Abandoned
- 2010-06-14 WO PCT/IB2010/052652 patent/WO2010143170A2/en not_active Ceased
- 2010-06-14 EP EP22193611.5A patent/EP4198022A1/en active Pending
- 2010-06-14 LT LTEPPCT/IB2010/052651T patent/LT2440547T/lt unknown
- 2010-06-14 CA CA2764027A patent/CA2764027C/en active Active
- 2010-06-14 ES ES10728369T patent/ES2940885T3/es active Active
- 2010-06-14 DK DK10757474.1T patent/DK2440547T3/da active
- 2010-06-14 CN CN201710158474.2A patent/CN106928194B/zh active Active
- 2010-06-14 HU HUE10728368A patent/HUE045548T2/hu unknown
- 2010-06-14 MX MX2015016291A patent/MX364279B/es unknown
- 2010-06-14 BR BRPI1010772A patent/BRPI1010772B8/pt active IP Right Grant
- 2010-06-14 JP JP2012514585A patent/JP6041671B2/ja active Active
- 2010-06-14 CN CN201710122014.4A patent/CN106905232B/zh active Active
- 2010-06-14 CA CA2764024A patent/CA2764024C/en active Active
- 2010-06-14 US US13/377,760 patent/US9145367B2/en active Active
- 2010-06-14 AU AU2010258294A patent/AU2010258294B2/en not_active Ceased
- 2010-06-14 DK DK10728369.9T patent/DK2440546T3/da active
- 2010-06-14 CN CN201510020820.1A patent/CN104945378B/zh active Active
- 2010-06-14 CN CN201080032055.0A patent/CN102596935B/zh active Active
- 2010-06-14 CN CN201080032045.7A patent/CN102625804B/zh active Active
- 2010-06-14 FI FIEP10757474.1T patent/FI2440547T3/fi active
- 2010-06-14 CN CN201080032036.8A patent/CN102574835B/zh active Active
- 2010-06-14 CA CA2764026A patent/CA2764026C/en active Active
- 2010-06-14 BR BRPI1010768A patent/BRPI1010768C8/pt active IP Right Grant
- 2010-06-14 KR KR1020177021820A patent/KR101863021B1/ko not_active Expired - Fee Related
- 2010-06-14 MX MX2016003039A patent/MX359575B/es unknown
- 2010-06-14 MX MX2011013122A patent/MX340095B/es active IP Right Grant
- 2010-06-14 MX MX2011013120A patent/MX338823B/es active IP Right Grant
- 2010-06-14 RU RU2011149571/04A patent/RU2567752C2/ru active
- 2010-06-14 TR TR2019/10781T patent/TR201910781T4/tr unknown
- 2010-06-14 DK DK19157827.7T patent/DK3517534T3/da active
- 2010-06-14 KR KR1020197004605A patent/KR102016890B1/ko active Active
- 2010-06-14 CN CN201910120757.7A patent/CN109776496B/zh active Active
- 2010-06-14 CN CN201510023124.6A patent/CN104844570B/zh active Active
- 2010-06-14 FI FIEP10728369.9T patent/FI2440546T3/fi active
- 2010-06-14 JP JP2012514587A patent/JP5905385B2/ja active Active
- 2010-06-14 JP JP2012514586A patent/JP5826745B2/ja active Active
- 2010-06-14 KR KR1020187025625A patent/KR101982462B1/ko not_active Expired - Fee Related
- 2010-06-14 KR KR1020187025624A patent/KR101973348B1/ko active Active
- 2010-06-14 CA CA3070823A patent/CA3070823C/en active Active
- 2010-06-14 ES ES19157827T patent/ES2985082T3/es active Active
- 2010-06-14 MX MX2015016292A patent/MX364280B/es unknown
- 2010-06-14 CN CN201510021597.2A patent/CN104945379B/zh active Active
- 2010-06-14 HR HRP20240582TT patent/HRP20240582T1/hr unknown
- 2010-06-14 MX MX2015016290A patent/MX364282B/es unknown
- 2010-06-14 EP EP19157827.7A patent/EP3517534B1/en active Active
- 2010-06-14 KR KR1020127000915A patent/KR101789275B1/ko active Active
- 2010-06-14 PT PT191578277T patent/PT3517534T/pt unknown
- 2010-06-14 DK DK10728368.1T patent/DK2440545T3/da active
- 2010-06-14 BR BR122019013686-6A patent/BR122019013686B1/pt active IP Right Grant
- 2010-06-14 PT PT107283699T patent/PT2440546T/pt unknown
- 2010-06-14 BR BR122019013687A patent/BR122019013687B1/pt active IP Right Grant
- 2010-06-14 PL PL10728369.9T patent/PL2440546T3/pl unknown
- 2010-06-14 PT PT10728368T patent/PT2440545T/pt unknown
- 2010-06-14 HU HUE10757474A patent/HUE061262T2/hu unknown
- 2010-06-14 SI SI201032127T patent/SI2440547T1/sl unknown
- 2010-06-14 CN CN201510023109.1A patent/CN104844510B/zh active Active
- 2010-06-14 CN CN202110307700.5A patent/CN113004249A/zh active Pending
- 2010-06-14 EP EP10728368.1A patent/EP2440545B1/en active Active
- 2010-06-14 CU CUP2015000024A patent/CU24245B1/es unknown
- 2010-06-14 WO PCT/IB2010/052650 patent/WO2010143168A2/en not_active Ceased
- 2010-06-14 KR KR1020177031675A patent/KR101897221B1/ko active Active
- 2010-06-14 CU CU2011000230A patent/CU24093B1/es active IP Right Grant
- 2010-06-14 ES ES10757474T patent/ES2938532T3/es active Active
- 2010-06-14 KR KR1020197004604A patent/KR102016889B1/ko active Active
- 2010-06-14 EP EP19157824.4A patent/EP3521283B1/en active Active
-
2011
- 2011-12-08 ZA ZA2011/09031A patent/ZA201109031B/en unknown
- 2011-12-08 ZA ZA2011/09032A patent/ZA201109032B/en unknown
-
2013
- 2013-11-22 US US14/087,762 patent/US9108919B2/en active Active
-
2014
- 2014-04-18 US US14/256,334 patent/US9908869B2/en active Active
-
2015
- 2015-04-27 JP JP2015090437A patent/JP2015155453A/ja active Pending
- 2015-06-15 JP JP2015120568A patent/JP6158251B2/ja active Active
- 2015-06-15 JP JP2015120567A patent/JP6158250B2/ja not_active Expired - Fee Related
- 2015-06-15 JP JP2015120566A patent/JP2015187150A/ja not_active Withdrawn
- 2015-07-01 US US14/789,250 patent/US10017498B2/en active Active
- 2015-07-01 US US14/789,149 patent/US9637475B2/en active Active
-
2019
- 2019-10-18 JP JP2019191500A patent/JP7042245B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20110228A7 (es) | Compuestos útiles para tratar envejecimiento prematuro y en particular progeria | |
| CL2021001330A1 (es) | Nuevos compuestos heterocíclicos | |
| CL2021000361A1 (es) | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa | |
| CR20180442A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| PE20200936A1 (es) | Dihidrooxadiazinonas | |
| CO2023014721A2 (es) | Compuestos heterocíclicos | |
| CU20190043A7 (es) | 8-cloro-o-quinoleínas y sus derivados como activos anti-inflamatorios | |
| NI200900164A (es) | COMPUESTOS AMINO- 5 -[ -4- (DIFLUOROMETOXI) FENIL SUSTITUIDO] -5- FENILIMIDAZOLONA COMO INHIBIDORES DE Beta - SECRETASA. | |
| CL2022000019A1 (es) | Nuevos compuestos heterocíclicos | |
| BR112016002063A2 (pt) | composto de tetrazolinona e uso do mesmo | |
| CL2020002217A1 (es) | Uso de alcoxipirazoles como inhibidores de la nitrificación | |
| UY38941A (es) | Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas | |
| BR112013008675A2 (pt) | métodos e composições para o tratamento de diabetes e dislipidemia | |
| MX2019008390A (es) | Compuestos utiles para tratar cancer. | |
| BR112018008885A8 (pt) | composto heterocíclico condensado | |
| CO6460700A2 (es) | Compuesto de pirazol | |
| BR112017027361A2 (pt) | agente para suprimir odores de compostos polissulfetados | |
| CR20160142A (es) | Pirido [4,3-b]pirazín-2-carboxamidas como agentes neurogénicos para el tratamiento de trastornos neurodegenerativos | |
| MX2018010535A (es) | Derivado de 5-metil-6-fenil-4,5-dihidro-2h-piridazin-3-ona. | |
| BR112020005364B8 (pt) | Composição reticulável, kit de partes, módulo aglutinante, e, método para prover um revestimento | |
| AR087825A1 (es) | Procedimiento para la preparacion de compuestos de pirazol n-sustituido | |
| PL416613A1 (pl) | Nowe związki heterocykliczne i sposób ich otrzymywania | |
| MX2021011902A (es) | Agente antimicrobiano. | |
| PL408240A1 (pl) | Mono-chloro pochodne 9,10-antrachinonu i sposób otrzymywania mono-chloro pochodnych 9,10-antrachinonu | |
| BR112017018764A2 (pt) | compostos de tetrazolinona e uso dos mesmos |